|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
BEFREE |
Overall, our results show how CtBP2 contributes to prostate cancer progression by modulating AR and oncogenic signaling.
|
25228652 |
2014 |
|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
BEFREE |
These results highlight the association between CtBP2 and angiogenesis in PCa and indicate that CtBP2 may be a potential therapeutic target for PCa.
|
28677795 |
2017 |
|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
BEFREE |
Taken together, our investigations demonstrated that low-expression of CtBP2 could highly inhibit proliferation of prostate cancer by c-Myc induced signaling, suggesting that targeting CtBP2 may yield a viable anti-tumor strategy by restraining tumor progression in prostate cancer.
|
24835310 |
2014 |
|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
BEFREE |
Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
|
24332637 |
2014 |
|
Malignant neoplasm of prostate
|
0.460 |
GeneticVariation
|
disease |
BEFREE |
After allowing for multiple testing, none of the SNPs examined were significantly associated with growth factor or hormone concentrations, and the SNP-prostate cancer associations did not differ by these concentrations, although 4 interactions were marginally significant (MSMB-rs10993994 with androstenedione (uncorrected P = 0.008); CTBP2-rs4962416 with IGFBP-3 (uncorrected P = 0.003); 11q13.2-rs12418451 with IGF-1 (uncorrected P = 0.006); and 11q13.2-rs10896449 with SHBG (uncorrected P = 0.005)).
|
22459122 |
2012 |
|
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
BEFREE |
Antimony enhances c-Myc stability in prostate cancer via activating CtBP2-ROCK1 signaling pathway.
|
30098506 |
2018 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
These results highlight the association between CtBP2 and angiogenesis in PCa and indicate that CtBP2 may be a potential therapeutic target for PCa.
|
28677795 |
2017 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
Taken together, our investigations demonstrated that low-expression of CtBP2 could highly inhibit proliferation of prostate cancer by c-Myc induced signaling, suggesting that targeting CtBP2 may yield a viable anti-tumor strategy by restraining tumor progression in prostate cancer.
|
24835310 |
2014 |
|
Prostate carcinoma
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
After allowing for multiple testing, none of the SNPs examined were significantly associated with growth factor or hormone concentrations, and the SNP-prostate cancer associations did not differ by these concentrations, although 4 interactions were marginally significant (MSMB-rs10993994 with androstenedione (uncorrected P = 0.008); CTBP2-rs4962416 with IGFBP-3 (uncorrected P = 0.003); 11q13.2-rs12418451 with IGF-1 (uncorrected P = 0.006); and 11q13.2-rs10896449 with SHBG (uncorrected P = 0.005)).
|
22459122 |
2012 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
|
24332637 |
2014 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
Overall, our results show how CtBP2 contributes to prostate cancer progression by modulating AR and oncogenic signaling.
|
25228652 |
2014 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
Antimony enhances c-Myc stability in prostate cancer via activating CtBP2-ROCK1 signaling pathway.
|
30098506 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As CtBP2 is targetable by an inhibitor of its dehydrogenase domain, understanding CtBP2's role in adenoma formation is necessary to optimize CtBP-targeted therapies in <i>Apc</i> mutated human neoplasia.
|
30197752 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that CtBP2 was overexpressed in GC tissues and closely correlated with poor differentiation, advanced tumor stage and poor prognosis in GC patients.
|
28404932 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A small-molecule inhibitor of CtBP2, 4-chloro-hydroxyimino phenylpyruvate (4-Cl-HIPP) phenocopied Ctbp2 deletion, decreasing tumor burden similarly to gemcitabine, and the combination of 4-Cl-HIPP and gemcitabine further synergistically suppressed tumor growth.
|
31586042 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion.
|
25686837 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CtBP2, as a transcriptional corepressor of epithelial-specific genes, has been reported to promote tumor due to upregulating epithelial-mesenchymal transition (EMT) in cancer cells.
|
25820824 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, ARF can suppress cell migration by antagonizing CtBP2 and the phosphatidylinositol 3-kinase pathway, and these data may explain the increased aggressiveness of ARF-null tumors in mouse models.
|
17909040 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CtBP2 proteins are ubiquitously expressed in all lines and tumour samples.
|
20964627 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our investigations demonstrated that low-expression of CtBP2 could highly inhibit proliferation of prostate cancer by c-Myc induced signaling, suggesting that targeting CtBP2 may yield a viable anti-tumor strategy by restraining tumor progression in prostate cancer.
|
24835310 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased MDSC density and tumor microRNA101 expression predict poor survival, as does decreased tumor CtBP2 expression, independent of each other.
|
24012420 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consistent with its function as a transcriptional corepressor, CtBP2 repressed tumor-suppressor genes and AR corepressors in prostate cancer cells, such as NCOR and RIP140, by binding with AR to the promoter enhancers of these genes.
|
25228652 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
C-terminal binding protein-2 (CtBP2), as a transcriptional co-repressor, has been shown to mediate the repression of p16(INK4A) , a tumor suppressor gene product, in primary human cells.
|
23255392 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Functional assays, including colony formation, wound healing, transwell invasion, anchorage-independent growth assay and a xenograft tumor model were used to determine the oncogenic role of CtBP2 in breast cancer progression.
|
28412731 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CtBP2 is thus a druggable transforming oncoprotein critical for the evolution of neoplasia driven by Apc mutation.
|
28414304 |
2017 |